Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN L A versus PENTIDS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN L A versus PENTIDS 250.
BICILLIN L-A vs PENTIDS '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release formulation that provides prolonged tissue concentrations. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes, leading to cell lysis.
Penicillin G binds to penicillin-binding proteins (PBPs) located on the bacterial cell wall, inhibiting transpeptidase activity and cell wall synthesis, leading to bacterial lysis.
1.2 million units intramuscularly as a single dose for treatment of streptococcal pharyngitis; for syphilis, 2.4 million units intramuscularly weekly for 1-3 weeks depending on stage.
250 mg orally every 8 hours.
None Documented
None Documented
Terminal half-life: 30-60 hours (prolonged due to slow absorption from IM depot; clinically allows single-dose regimen for syphilis)
0.5-1 hour (prolonged in renal impairment; requires dose adjustment when CrCl <30 mL/min)
Renal: 60-90% unchanged; biliary/fecal: minor (<10%)
Primarily renal (60-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (10-30%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic